Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Methodist Hospital Research Institute
Boehringer Ingelheim
Eli Lilly and Company
Tomsk National Research Medical Center of the Russian Academy of Sciences
Daiichi Sankyo
National Cancer Institute (NCI)
AstraZeneca
EMD Serono
Pfizer
Genentech, Inc.
Werewolf Therapeutics, Inc.
Novartis
ModernaTX, Inc.
EMD Serono
M.D. Anderson Cancer Center
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
University Health Network, Toronto
Daiichi Sankyo
Chinese PLA General Hospital
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Kansas Medical Center
Turning Point Therapeutics, Inc.
M.D. Anderson Cancer Center
Adaptimmune
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Ono Pharmaceutical Co. Ltd
invoX Pharma Limited
Daiichi Sankyo
Memorial Sloan Kettering Cancer Center
BeiGene
AbbVie
Memorial Sloan Kettering Cancer Center
Hummingbird Bioscience
Daiichi Sankyo
National Cancer Institute (NCI)
Carisma Therapeutics Inc
Revolution Medicines, Inc.